Structure Therapeutics (GPCR) Free Cash Flow (2022 - 2026)

Structure Therapeutics' Free Cash Flow history runs 5 years deep, the most recent figure standing at $14.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 126.4% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at -$158.5 million (down 12.57% YoY), while the FY2025 annual figure was -$225.8 million, down 85.55% from the prior year.
• Free Cash Flow for Q1 2026 stood at $14.1 million, up from -$66.5 million in the prior quarter.
• The five-year high for Free Cash Flow was $14.1 million in Q1 2026, with the low at -$66.5 million in Q4 2025.
• The 5-year median for Free Cash Flow is -$20.9 million (2023), against an average of -$27.0 million.
• The sharpest annual moves came in 2025 and 2026: Free Cash Flow plunged 154.86% in 2025, then soared 126.4% in 2026.
• Structure Therapeutics' Free Cash Flow stood at -$12.0 million in 2022, then plunged by 78.85% to -$21.5 million in 2023, then sank by 87.53% to -$40.3 million in 2024, then slumped by 65.29% to -$66.5 million in 2025, then jumped by 121.12% to $14.1 million in 2026.
• Business Quant data shows GPCR's Free Cash Flow at $14.1 million in Q1 2026, -$66.5 million in Q4 2025, and -$51.9 million in Q3 2025.